查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571448

製藥市場的市場規模、佔有率和趨勢分析報告：按產品、經濟、適應症、地區和細分市場預測，2024-2030

Pharmerging Market Size, Share & Trends Analysis Report By Product (Pharmaceutical, Healthcare), By Economy (Tier-1, Tier-2), By Indication (Lifestyle Disease, Infectious Disease), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

醫藥市場的成長與趨勢：

預計2030年全球醫藥市場規模將達2.8兆美元，2024年至2030年複合年成長率預計為2.6%。

由於老年人口的增加、慢性病造成的疾病負擔的增加以及醫療保健支出的增加，預計該市場將會擴大。

根據聯合國 (UN) 統計，2015 年 60 歲及以上人口估計為 9.01 億。日益成長的老齡化人口將推動對高血脂症、高血壓、失智症、失智症和鬱血性心臟衰竭等慢性疾病更好的治療選擇的需求。根據德勤2011年進行的一項研究，老年人口幾乎佔醫藥市場的23.0-40.0%，佔OTC醫藥市場的40.0-50.0%。推動醫藥市場的另一個因素是醫療支出的增加。

新興國家慢性病負擔的增加正在推動市場成長。根據全球健康觀察站的資料，2015年非傳染性疾病（NCD）佔死亡人數的70.0%。主要的非傳染性疾病是心血管疾病（CVD），佔非傳染性疾病死亡的45.0%；癌症，佔非傳染性疾病死亡的22.0%；慢性阻塞性肺病），佔非傳染性疾病死亡的10.0%；以及糖尿病。

製藥市場亮點

  • 製藥業佔市場主導地位，2023 年收益佔有率最大，為 85.0%。
  • 一級經濟體將引領市場，到 2023 年市場佔有率最大，達 60.5%。
  • 關鍵策略舉措包括新產品發布、收購/合併和聯盟。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章醫藥市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 醫藥市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 醫藥市場：產品評估與趨勢分析

  • 細分儀表板
  • 製藥市場：2023 年和 2030 年按產品分類的波動分析
  • 製藥
  • 其他醫療保健產業

第5章醫藥市場：經濟預測與趨勢分析

  • 細分儀表板
  • 醫藥市場：2023 年與 2030 年經濟變遷分析
  • 1層級
  • 2層級
  • 3層級

第6章 醫藥市場：適應症估計與趨勢分析

  • 細分儀表板
  • 醫藥市場：2023 年和 2030 年按適應症變化分析
  • 文明病
  • 癌症與自體免疫疾病
  • 感染疾病
  • 其他

第7章 醫藥市場：區域估計與趨勢分析

  • 2023 年及 2030 年按地區分類的製藥市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Sanofi
    • Pfizer Inc.
    • AstraZeneca
    • GlaxoSmithKline
    • F. Hoffmann-La Roche Ltd.
    • GE Healthcare
    • Eli Lilly and Company
    • Medtronic
    • Abbott
    • Johnson and Johnson
簡介目錄
Product Code: GVR-2-68038-256-3

Pharmerging Market Growth & Trends:

The global pharmerging market size is expected to reach USD 2.08 trillion in 2030 and is projected to grow at a CAGR of 2.6% from 2024 to 2030. This market is expected to grow due to the increasing geriatric population, increasing disease burden of chronic disorders, and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years is estimated to be 901 million in 2015. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market. Another driving factor for the pharmerging market is increasing healthcare expenditure.

The increasing disease burden of chronic diseases in developing countries is boosting growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Pharmerging Market Report Highlights:

  • The pharmaceutical product segment dominated the market and accounted for the largest revenue share of 85.0% in 2023.
  • The tier-1 economy led the market, accounting for the largest market share at 60.5% in 2023.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmerging Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pharmerging Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pharmerging Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pharmerging Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Pharmaceutical
    • 4.3.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.1. Patented Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.2. Generic Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.3.1.3. OTC Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Other Healthcare Verticals
    • 4.4.1. Other Healthcare Verticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Medical Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.2. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.3. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Pharmerging Market: Economy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pharmerging Market: Economy Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Tier-1
    • 5.3.1. Tier-1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Tier-2
    • 5.4.1. Tier-2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Tier-3
    • 5.5.1. Tier-3 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Pharmerging Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pharmerging Market: Indication Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Lifestyle Diseases
    • 6.3.1. Lifestyle Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Cancer & Autoimmune Diseases
    • 6.4.1. Cancer & Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Infectious Diseases
    • 6.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Pharmerging Market: Regional Estimates & Trend Analysis

  • 7.1. Pharmerging Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pharmerging Market Estimates and Forecasts, 2018 - 2030) (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Sanofi
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GlaxoSmithKline
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. F. Hoffmann-La Roche Ltd.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. GE Healthcare
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Eli Lilly and Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Medtronic
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Abbott
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson and Johnson
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives